There are substantial differences between individuals with regard to their risk of developing cancer, of progressing to high-grade tumours and in response to therapies. This heterogeneity is a major obstacle to designing uniformly effective prevention, screening and treatment strategies and it motivates the large effort to personalize these strategies using biomarkers 1 . Commonly inherited genetic variants, such as single nucleotide poly morphisms (SNPs) hold great promise as easily obtainable and measurable biomarkers. More than 1,000 SNPs have been shown to associate significantly with human cancer in genome-wide association studies (GWAS) conducted in a broad range of solid and haematological malignancies. However, despite these findings, major challenges remain in translating these associations into clinical applications 2, 3 . For example, discerning the functional consequences of the variant, as well as the genes and molecular pathways connecting the variant with disease, has proved extremely challenging. This limited understanding of the biology behind these significant associations has clearly constrained our ability to integrate SNP biomarkers into the proper genetic, cellular and clinical context to maximize their effective use in the clinic.
In recent years, the field of human genetics has made great strides in generating datasets that are crucial for revealing the mechanistic relationship between SNPs and tumorigenesis. For example, data generated by the 1000 Genomes Project reveal the genetic diversity in individuals and populations and have been crucial for identifying haplotypes that are linked to diseases studied with GWAS 4 . Moreover, functional genomic scans of gene regulatory features, such as transcription factor binding or specific histone modifications, using chromatin immuno precipitation coupled with sequencing (ChIP-seq) can connect these SNPs with functional biological differences [5] [6] [7] [8] . Additionally, the advent of expression quantitative trait loci (eQTL) mapping approaches that measure gene expression levels for tens of thousands of transcripts in genotyped samples has provided an intermediate biological phenotype that is useful for interpreting many GWAS associations. In these studies, global gene expression measurements and whole-genome SNP genotypes are correlated in order to connect the abundance of a specific gene transcript with an allelic variant and define eQTLs [9] [10] [11] . Analysis of datasets such as these enables rapid assignment of cancer-associated SNPs to well-studied signalling pathways that are known to be important in a broad range of cancers and for which somatic genetic variants are currently used as biomarkers or drug targets in the laboratory and clinic. Identifying which cancerassociated pathways frequently carry SNPs associated Genome-wide association studies (GWAS) . Analysis of the association of genetic variants, typically single nucleotide polymorphisms (SNPs), with a specific trait or disease. They are often very large case-control studies in which SNPs throughout the whole genome are examined for differences in allele frequencies between the two different populations. Decades of research have shown that mutations in the p53 stress response pathway affect the incidence of diverse cancers more than mutations in other pathways. However, most evidence is limited to somatic mutations and rare inherited mutations. Using newly abundant genomic data, we demonstrate that commonly inherited genetic variants in the p53 pathway also affect the incidence of a broad range of cancers more than variants in other pathways. The cancer-associated single nucleotide polymorphisms (SNPs) of the p53 pathway have strikingly similar genetic characteristics to well-studied p53 pathway cancer-causing somatic mutations. Our results enable insights into p53-mediated tumour suppression in humans and into p53 pathway-based cancer surveillance and treatment strategies. 
Li-Fraumeni syndrome (LFS)
.
Multiple hypothesis testing
When testing many hypotheses simultaneously, the likelihood of one test reaching a significance threshold of P <0.05 increases. Thus, to reduce the likelihood of false positives, a multiple hypothesis testing correction is applied.
with differential cancer susceptibility could accelerate our biological understanding of the influence of the variants on cancer and the potential clinical utility of SNP biomarkers 12, 13 . One of the best studied and important cancer signalling pathways is the p53 tumour suppressor pathway. Decades of intensive research in mice and humans have shown that human genetic variants in the p53 stress response pathway can have key roles in the incidence and survival of many cancers. For example, among indivi duals with the very rare Li-Fraumeni syndrome (LFS) -who carry inherited, heterozygous mutations in TP53 (which encodes p53) -the pen etrance for cancer onset is 100% by the age of 70 years, with the cancers occurring in numerous tissues, including bone, connective tissues, breast and brain 14, 15 . Indeed, candidate SNP studies have clearly demonstrated that p53 signalling can be affected by functional SNPs that in some cases result in differential cancer susceptibility [16] [17] [18] . Moreover, very similar somatic mutations in the TP53 gene are found in more than 50% of all cancer genomes 19, 20 , making it the most frequently mutated gene that is causally implicated in cancer and the gene mutated in the broadest range of cancer types, including epithelial, mesenchymal and haematological cancers 19, 21 . Importantly, recent network analyses that have taken advantage of advances in high-throughput exome sequencing of cancer genomes have shown that the p53 pathway represents the largest, most frequently identified network of genes carrying mutations in the broadest spectrum of cancers identified thus far [22] [23] [24] [25] [26] [27] . In fact, common somatic mutations in many genes of the pathway are known to directly affect susceptibility to a broad range of cancer types and are being developed as crucial biomarkers to inform therapy in some patient-stratification strategies in the clinic 14, 16, 17, [28] [29] [30] . Moreover, these somatic mutations and low-frequency inherited mutations have been shown to affect cancer risk, progression and response to therapies for many cancers in humans and many mouse models. Such findings are consistent with the well-defined roles of the p53 stress response pathway in tumour suppression, regulating cell migration and invasion and mediating the cellular response to DNA damage-inducing cancer therapies, primarily through the ability of p53 to regulate transcription [31] [32] [33] [34] [35] . These observations made in model systems, tumour studies and in a rare familial syndrome (LFS) suggest that genetic variants found in the general human population, such as SNPs, would also be more likely to affect susceptibility to a broader range of cancer types than functional SNPs in other genes and pathways. In this Analysis, we demonstrate that the abundant genomic data generated in the past decade support this prediction. We go on to show that these common SNP variants are similar to well-studied inherited and somatic p53 pathway disease-associated mutations, in that they are frequently found in a high proportion of p53 pathway genes and they associate with multiple types of cancer, but not other diseases. Moreover, they are found almost exclusively in p53 pathway genes that can carry cancer-causing mutations in cancer genomes, thereby suggesting that particular p53 pathway genes are highly sensitive to heritable and somatic genetic variants, resulting in altered tumour suppression in many tissue types. Our results also support a causal relationship between certain classes of RNAprocessing SNPs in p53 pathway genes and the noted differential cancer risk.
Cancer variants in p53 pathway genes Somatic, causal mutations. Cancer driver genes, such as TP53, when mutated, can promote tumorigenesis and have been identified through studies of inherited cancer predisposition syndromes, cancer genome sequencing and experimental models of cancer. Although estimates regarding the exact number of these genes vary, one wellused curated list is the COSMIC Cancer Gene Census, which uses sequencing data to identify genes for which the number and pattern of mutations are highly unlikely to be attributable to chance 36 . The current list consists of 493 RefSeq autosomal genes that harbour somatic cancer-promoting mutations. Of the 67 auto somal genes attributed to the p53 pathway (according to the Kyoto Encyclopedia of Genes and Genomes (KEGG)), 15 have been denoted as harbouring somatic, causal mutations in at least one cancer type. This group includes the well-studied oncogenes and tumour suppressor genes ataxia telangiectasia mutated (ATM), MDM2, cyclindependent kinase inhibitor 2A (CDKN2A; which encodes INK4A and ARF), FAS and MDM4 (FIG. 1a) . Thus, 22.38% of genes of the p53 pathway contain known causal mutations; a significant 11.15-fold enrichment over the 2.01% found in all 24,553 annotated autosomal genes (FIG. 1b; RefSeq, P = 3.74e -12 , adjusted for multiple hypothesis testing P = 8.22e -10 ). In order to assess further the importance of the 11.15-fold enrichment of cancer-associated causal mutations in genes of the p53 pathway, we compared it with potential fold enrichments of causally mutated genes in all well-annotated pathways in the genome. To do this, we determined potential enrichments in all 220 signalling pathways annotated by KEGG in the categories of metabolism, genetic information processing, environmental information processing, cellular processes and organismal systems. We found that 66 of the 220 cellular signalling pathways (30%), including the p53 pathway, demonstrated significant enrichment of causally mutated genes after correction for multiple hypothesis testing (FIG. 1c; see Supplementary information S1 (methods) and Supplementary information S2 (table) for details). Thus, the enrichment noted in the p53 pathway places it among the top 5% of all well-annotated pathways of the genome. The other significantly enriched pathways also include frequently mutated tumour suppressor genes and oncogenes, such as PI3K catalytic subunit-α (PIK3CA), adenomatous polyposis coli (APC) and KRAS
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(Supplementary information S2 (table)). It is important to note that the enrichment of causally mutated genes in the p53 pathway was also found to be in the top 5% of all pathways when we used a list of causally mutated genes generated using various criteria by different researchers , the significant enrichment of causally mutated genes in the p53 pathway suggests that inherited SNPs in p53 pathway genes could affect cancer susceptibility to a greater extent than SNPs in other annotated signalling pathways. To begin to test this, we used the GWAS catalog (download date: 12 October 2015) and the 10th revision of International Classification of Diseases (ICD10) to identify all cancer susceptibility GWAS studies that have been undertaken to date (Supplementary information S1 (methods)). We first identified all GWAS studies that were designed to study disease susceptibility and noted that the vast majority of studies have been performed in European populations (n = 756). Each of the 756 GWAS can be attributed to one of the major ICD10 disease categories, which include Neoplasms (Supplementary information S4 (table)). We found that 19 different ICD10 disease categories have at least one GWAS study (average: 39.8 studies per disease category). Importantly for this Analysis article, Neoplasms had the most studies attributed to it with 165. These 165 studies were undertaken to assess differential susceptibility to a broad range of cancers (ICD10 subcategory, Supplementary information S4 (table)) with a median of 11,647.5 individuals with cancer per study. If our hypothesis is correct, we would expect that genes of the p53 pathway would overlap with the cancer susceptibility loci (CSLs) identified in these GWAS studies to a greater extent than the genes of other well-defined signalling pathways.
To test this, we first determined which CSLs mapped to the 24,553 autosomal RefSeq genes in the genome. We began by using the 1000 Genomes Phase 3 dataset to identify all known SNPs (minor allele frequency (MAF) ≥0.001) from European populations within ±10 kb of the gene boundaries of the 24,553 autosomal RefSeq genes and found 7,106,459 SNPs in total. Subsequently, we mined the GWAS catalogue, and extracted the 1,034 SNPs (750 unique loci) associated with susceptibility to approximately 17 different types of cancer in European populations, including epithelial, mesenchymal and haematological cancers (FIG. 2) .
Next, we augmented this dataset with SNPs in linkage disequilibrium (LD) (r 2 = 1.0, MAF ≥0.001) in European populations using data from the 1000 Genomes Phase 3 dataset. On average, a cancer GWAS SNP was in perfect LD with 4.926 SNPs (range 1-126 SNPs), and the linked SNPs spanned an average genomic region of 6,947.132 bp (range 1-201,267 bp). Our final dataset consists of a total of 3,454 unique cancer GWAS SNPs.
Using our parameters, which require at least one cancer GWAS SNP to reside within ±10 kb of an annotated gene body, we determined that 2,262 (65.5%) of 3,454 cancer GWAS SNPs mapped to 541 autosomal genes, which we refer to as cancer susceptibility genes (CSGs; FIG. 3a ; Supplementary information S5 (table) ). Interestingly, 10 of the 67 p53 pathway genes (14.93%) are CSGs, namely: ATM, checkpoint kinase 2 (CHEK2), caspase 8 (CASP8), cyclin D1 (CCND1), CCND2, CCNE1, CDKN2A, FAS, MDM4 and TP53. This 14.93% of p53 pathway genes represents a significant 6.77-fold enrichment compared with the 2.2% of 24,553 annotated autosomal genes that are CSGs (P = 2.00e -06 , adjusted
It is important to note that all but one p53 pathway CSG (MDM4) have been attributed to at least one other KEGG annotated pathway. Thus, in order to assess further the importance of the 6.77-fold enrichment of CSGs in the p53 pathway, we compared it with the potential enrichment of CSGs in all 220 wellannotated pathways in the genome. Only 3 of these 220 cellular signalling pathways (1.36%), including the p53 pathway, demonstrated significant enrichments of CSGs after correction for multiple hypothesis testing (FIG. 3c; Supplementary information S6 (table)). The two other significant pathways are PI3K-AKT and Adherens Junction. Like the p53 pathway, these are also known to be important pan-cancer signalling pathways (KEGG cancer signalling pathways). However, the enrichment of CSGs in the p53 pathway ranks highest for both the level of significance and the fold enrichment (FIG. 3c) . Specifically, the PI3K-AKT and Adherens Junction pathways are associated with fold enrichments of 2.73 (P = 5.42e -05 ) and 5.11 (P = 1.66e -04 ), respectively, compared with a fold enrichment of 6.77 (P = 2.00e -06 ) for the p53 pathway. Together, the results of these analyses thus far suggest that in the p53 pathway somatic, causal mutations and inherited cancer-associated SNPs occur in a high proportion of p53 pathway genes relative to other pathways.
Expression quantitative trait loci. The fact that in the above analyses we required that one or more of the cancer GWAS SNPs reside within 10 kb of gene boundaries to define CSGs increases the likelihood that a SNP will be cis-acting and will functionally affect expression of its proximal gene or the protein it encodes. However, in order to gain more certainty that the SNPs can functionally affect the genes in which they reside, we further restricted our analyses to those SNPs, in and around genes, with genotypes that also associate with mRNA levels of their proximal genes in expression quantitative trait loci (eQTL) studies (cis-acting, cis-eSNPs). To do this, we began by curating data from 14 publicly available 75 .06% were found to be in a single tissue, 16.05% in two tissues, 6% in three tissues and 2.89% in four or more tissues.
In total, we identified 11,887 genes genome-wide that harboured cis-eSNPs. In 133 of these genes (1.12%), we observed that the eSNPs also overlap (that is, are in complete LD) with cancer GWAS SNPs. Thus, these genes harbour haplotype blocks that associate with both differential cancer susceptibility and proximal gene expression in at least one tissue or cell type analysed (eCSGs; FIG. 4a ; Supplementary information S5 (table) ). Interestingly, 6 of the eCSGs are among the 51 p53 pathway genes that harbour cis-eSNPs (11.76%): FAS, MDM4, ATM, CCND1, CASP8 and CCNE1. This represents a significant 10.51-fold enrichment compared with the 1.12% found in all 11,887 annotated genes that harbour at least one cis-eSNP (P = 2.09e (table) ); in fact, 61.8% of pathways do not have any eCSGs. These results demonstrate that even when we restrict our analyses to SNPs that can associate with differential gene expression of their proximal genes, cancer-associated SNPs still occur in a high proportion of pathway genes relative to all annotated signalling pathways.
p53 genes are not enriched in SNPs associated with other diseases. These results clearly lend support to the hypothesis that commonly inherited genetic variation in p53 pathway genes will affect cancer susceptibility to a greater extent than the variation found in genes of other pathways. However, the p53 stress response pathway has also been implicated in the pathogenesis of many other diseases that have been studied in GWAS, including neurological [52] [53] [54] [55] [56] , cardiovascular 57, 58 and infectious 59, 60 diseases. Therefore, we next explored the potential impact of p53 pathway SNPs on susceptibility to non-cancerous disease. To do this, we took advantage of the 591 GWAS studies that have been carried out to measure the genetic basis of differences in susceptibility to other non-cancer diseases in Europeans. As mentioned above, 18 ICD10 disease categories, other than Neoplasms, had at least one susceptibility GWAS study attributed to it (Supplementary information S4 (table)). In the same manner as described above for our analysis of the 165 cancer GWAS (ICD10 category Neoplasms), we identified a set of genes for each of the other 18 disease categories in which at least one GWAS SNP was found to reside within ±10 kb of chr1 chr2 chr3 chr4 chr5 chr6 chr7 chr8 chr9 chr10 chr11 chr12 chr13 chr14 chr15 chr16 chr17 chr18 chr19 chr20 chr21 chr22 (FIG. 3) of the p53 pathway overlap with cancer GWAS loci to a greater extent than the genes of 219 other well-annotated signalling pathways, and that this enrichment is limited to cancer GWAS (FIG. 5) . Thus far, we have exclusively used KEGG pathway annotations for our analyses. In order to explore further the significance of our observations, we extended our analyses to pathway annotations from two different wellused, curated pathway databases, namely BioCarta and PANTHER. Similar to the findings using KEGG pathway annotation, the enrichment of CSGs in the p53 pathway ranks highest for the level of significance relative to all other pathways annotated by either BioCarta (FIG. 6a ; ). c | A scatter plot showing the fold enrichment of CSGs on the x-axis (log 2 scale), and the adjusted P-value on the y-axis (-log 10 scale). The horizontal dashed line represents the 5% family-wise error rate threshold (Bonferroni-adjusted P = 0.05), which is the pre-fixed significance threshold. The enrichment of CSGs in p53 pathway genes (in yellow) is the highest and the most significant compared with the other 220 annotated Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (in blue). Overall, 1.36% of pathways demonstrated significant enrichments of CSGs. chr, chromosome. (table) ). Also similar to the analyses conducted with KEGG annotation, when we explored the potential enrichment of p53 pathway genes among the susceptibility loci of the other 18 disease groupings defined above, we found no significant enrichment for the p53 signalling pathway annotated by either database (FIG. 6a,b , additional panels).
p53 pathway variants among cancers Causal mutations. As mentioned above, the ability of p53 to suppress tumour formation in numerous tissues has been demonstrated in several mouse models 29, 30, 61 . Indeed, some of the genes of the p53 pathway have been found to be causally mutated in cancer genomes from all four major annotated tissue type groupings: epithelial, mesenchymal, leukaemia or lymphoma and other (COSMIC). In FIG. 1 , we demonstrate that p53 pathway genes are enriched in genes known to harbour causal, somatic mutations in at least one of these four tissue types, whereby the enrichment noted places the p53 pathway among the top 5% of all annotated pathways of the genome (KEGG). Interestingly, we find similar significant enrichments when we restrict our ana lyses to causal, somatic mutations found in the various cancer types. We find that, in all four major cancer types, p53 pathway genes were enriched in causally mutated genes (FIG. 7a) . Six cis-eCSGs are found among the 67 genes of the p53 pathway, which represents a significant 10.51-fold enrichment compared with the 11,887 genes with at least one eSNP (P = 2.09e -05 denoted in the graph, adjusted P = 4.59e -03
). c | A scatter plot showing the fold enrichment of eCSGs on the x-axis (log 2 scale), and the adjusted P-value on the y-axis (-log 10 scale). The horizontal dashed line represents the 5% family-wise error rate threshold (Bonferroni-adjusted P = 0.05), which is the pre-fixed significance threshold. The enrichment of cis-eCSGs in the genes of the p53 pathway (in yellow) is the highest and the most significant compared with all the other Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (in blue). Overall, 0.45% of pathways demonstrated significant enrichment of cis-eCSGs. chr, chromosome. Cancer-associated SNPs. Given the observation that the p53 pathway belongs to the 5.9% of all 220 signalling pathways that are enriched in causally mutated genes in all four major cancer types, we next wanted to explore whether similar observations can be found among the cancer-associated SNPs. In FIG. 3 , we demonstrate that p53 pathway genes are enriched in genes overlapping CSLs (CSGs), whereby the noted 6.77-fold enrichment places the p53 pathway at the top of all 220 annotated signalling pathways for CSG enrichment (KEGG). However, we also find similar significant enrichments when we restrict our analyses to CSLs found in the individual cancer types.
In epithelial cancers, 10.45% of the 67 p53 pathway genes are CSGs, which represents a 6.59-fold enrichment over the 1.58% CSGs found in all 24,553 annotated autosomal genes (P = 9.12e -05 , adjusted P = 2.01e -02 ; FIG. 7c) . Interestingly, only the p53 pathway demonstrated significant enrichments of CSGs after correction for multiple hypothesis testing (FIG. 7c) ). No significant enrichments were noted for any of the 220 pathways in the mesenchymal cancers or cancers in the Other category. However, this is probably due to the relatively fewer number of studies that have been carried out in these categories of cancer (FIG. 2a) . Importantly, and as seen in FIG. 7d , only the genes of the p53 pathway are significantly enriched in CSGs in more than one cancer type. Together, these results clearly demonstrate that p53 pathway mutations and cancer-associated SNPs both occur in a high proportion of p53 pathway genes in multiple cancer types relative to other cellular signalling pathways. 19 International Classification of Diseases revision 10 (ICD10) disease groups that had at least one pathway significantly enriched in SGs. The fold enrichment of SGs is on the x-axis (log 2 scale) and the adjusted P-value is on the y-axis (-log 10 scale). The horizontal dashed line represents the 5% family-wise error rate threshold (Bonferroni-adjusted P = 0.05), which is the pre-fixed significance threshold. The enrichment of p53 pathway SGs are shown in yellow; significant enrichment is observed in cancer (Neoplasms), but not in any other disease groups. SNPs and mutations in similar p53 genes As mentioned above, of the 67 autosomal genes attributed to the p53 pathway (KEGG), 15 have been denoted as harbouring somatic, causal mutations in at least one cancer type (COSMIC). In our analysis thus far, we determined that 9 of these genes (60%) are CSGs (FIG. 8a) . This represents a significant 4.02-fold enrichment compared with the 10 CSGs (14.93%) found in all 67 p53 pathway genes (hypergeo metric test, P = 1.06e -6 ; FIG. 8c ). This dramatic enrichment clearly demonstrates that genes in the p53 pathway known to harbour causal somatic mutations in cancer genomes are more likely to also harbour SNPs associated with differential cancer risk as measured in GWAS. However, it is important to note that this is not limited to the genes of the p53 pathway. Specifically, similar enrichments, albeit smaller, can be found among causally mutated genes that are not in the p53 pathway. For example, when we restrict our analysis to the 478 causally mutated genes not attributed to the p53 pathway (KEGG), we observe a significant enrichment of CSGs relative to the 24,486 non-p53 pathway genes of the genome, but to a lesser degree (fold enrichment: 3.09; hypergeometric test, P = 2.12e p53 pathway SNPs and RNA processing In this study, we have determined that 50 SNPs in 10 p53 pathway genes (KEGG) have been either directly or indirectly found to associate with differential cancer risk in GWAS (average of 5 SNPs per gene, range 1-16; see Supplementary information S13-S14 (tables) for details). In contrast to causal somatic tumour mutations, cancer-associated SNPs are single nucleotide variations that, on average, cannot have negatively affected reproductive success, as they occur at relatively high frequencies in the human population. This obvious difference between inherited and somatic genetic variation results in the vast majority of SNPs having weaker net effects on protein activity, and ultimately cancer development, than somatic mutations. These lower penetrant effects represent a major ongoing challenge in determining the molecular underpinnings of significant SNP associations found in GWAS, along with the fact that the responsible, . However, for 2 of the 50 cancer-associated SNPs there is mounting experimental evidence that they reside in RNA-processing regulatory elements.
Specifically, one SNP, in the 3′ untranslated region (3′ UTR) of the TP53 gene (rs78378222, A/C) resides in a canonical polyadenylation signal sequence. This poly(A) SNP was identified in a GWAS for basal cell carcinoma, whereby the risk allele (C) is predicted to disrupt the poly(A) signal in the gene by changing AATAAA to AATACA 77 . Such a disruption of the poly(A) signal could impede cleavage of the nascent mRNA and addition of the poly(A) tail, ultimately resulting in less cellular p53 and potentially less p53-mediated tumour suppression. Two recent studies have provided data that support the proposal that the A to C change does result in aberrant 3′ end processing 77, 78 . The other regulatory SNP resides in a 5′ splice site (donor) at the exon 4-intron 4 boundary in the CCND1 gene (rs9344, 870G→A). This 5′ splice site SNP was found to associate with differential risk for t(11;14)(q13;q32) multiple myeloma in a GWAS, whereby the G-allele, which creates the stronger 5′ splice site (CCGgtaagt compared with CCAgtaagt), was found to associate with increased risk 79 . Alternative splicing of this exon and the potential role of this SNP in affecting the 5′ splice site was first reported more than 20 years ago 80 . Indeed, many subsequent studies conducted in various cell types have demonstrated an associ ation of the A-allele with less exon 4 splicing, resulting in the production of the cyclin D1b variant 79, 81, 82 . The functional influence of this variant on cancer risk, relative to the cyclin D1a variant, remains to be further elucidated. However, in non-GWAS this heavily studied SNP has frequently been found to associate with differential risk of many cancer types, such as basal cell carcinoma and renal cell carcinoma, bladder, breast, colorectal, oesophageal, gastro intestinal, head and neck, lung, ovarian and prostate cancer, and hepatoblastoma and leukaemia 83 . Together, these data clearly demonstrate that 2 of the 50 p53 pathway cancer GWAS SNPs reside in regulatory elements that affect differential RNA processing. If there is a causal relationship between the RNA processing SNPs and the noted differential cancer risk, we could expect similar RNA processing SNPs among the 16,890 p53 pathway SNPs to be significantly enriched in cancer GWAS. To test this, we determined the occurrence of similar poly(A) and 5′ splice site SNPs among all 16,890 SNPs in and around all 67 p53 pathway genes (KEGG). We identified only two additional SNPs that, like CCND1 rs9344, also reside in the exonic region of the 9-mer 5′ splice site sequences and are predicted to demonstrate similar allelic differences in splice site recognition. The additional two SNPs reside in the CCNB2 and thrombospondin 1 (THBS1) genes (Supplementary information S15 (table) ). Thus, of the three SNPs in the 5′ splice sites of p53 pathway genes, one (33.3%) is a cancer GWAS SNP (the above-mentioned CCND1 rs9344, 870G→A). This represents a significant enrichment compared with both the 50 (0.29%) cancer GWAS SNPs found among the total 16,890 p53 pathway SNPs (fold-enrichment 112.6; hypergeometric test P-value 0.0088) and the 3 (1.03%) cancer GWAS SNPs found among the 290 SNPs in coding exons (fold-enrichment: 32.22; hypergeometric test P-value 0.030). We identified four SNPs in AAUAAA poly(A) sites in four different pathway genes (TP53, protein phosphatase Mg 2+ /Mn 2+ dependent 1D (PPM1D), CCNG2, ribonucleo tide reductase regulatory TP53 inducible subunit M2B (RRM2B); Supplementary information S15 (table)). Of these 4 SNPs, only the one in TP53 (25%, rs78378222) is a cancer GWAS SNP; this represents a significant enrichment compared with both the 50 (0.29%) cancer GWAS SNPs found among the total 16,890 p53 pathway SNPs (fold-enrichment 84.45; P = 0.011) and the 3 (0.54%) cancer GWAS SNPs found among the 555 SNPs that occur in 3′ UTRs (foldenrichment 46.25; P = 0.021). It is important to note that no such significant enrichment was found among the missense coding SNPs, whereby of the 143 missense SNPs identified among the p53 pathway SNPs, 2 are cancer GWAS SNPs (1.4%; hypergeo metric test P-value 0.07 when compared with all pathway SNPs). Together, these results support a causal relationship between these classes of RNA processing SNP in p53 pathway genes and the noted differential cancer risk.
Discussion
Decades of research have clearly shown that genetic manipulation of p53 signalling can dramatically affect susceptibility to a broad range of cancers in mice and humans, and the topic has been well reviewed 14, 15, 21, 28, 30, 84 . However, most evidence has been restricted to the characterization of rare inherited mutations found in families with LFS and common somatic mutations found in cancer genomes (FIG. 1) . In this Analysis, we aimed to explore the possibility that commonly inherited genetic variants in the p53 pathway also have a significant role in susceptibility to a broad range of cancers. To do this, we used genome-wide datasets of genetic variation, CSLs derived from more than 165 GWAS conducted in a broad range of cancers (FIG. 2) and eQTLs from 14 different eQTL databases from 11 different noncancerous tissue or cell types. Specifically, we took an integrated bioinformatics approach that linked SNPs and haplotypes from the 1000 Genomes Project to cancer GWAS SNPs and eQTLs in genes expressed in many tissues. Our results demonstrate that p53 pathway genes are more significantly enriched in CSLs compared with other signalling pathways, regardless of the pathway annotation database (FIGS 3, 6) . Indeed, when we restricted our analyses to SNPs that reside in known cis-eQTLs, only the enrichment of the p53 pathway genes remained significant after multiple hypothesis correction (FIG. 4) . Moreover, we found that only the p53 pathway genes were significantly enriched in CSLs for different cancer types (FIG. 7) . We go on to show that the p53-associated cancer susceptibility loci are enriched in polymorphic regulatory elements for RNA processing. One of the most striking findings of our analyses are the strong similarities between the causal, somatic mutations and the inherited, cancer-associated SNPs of the p53 pathway. We have found that both classes of genetic variant occur in a high proportion of p53 pathway genes relative to other pathways (FIGS 1,3,6), in multiple cancer types (FIG. 7) and in similar pathway genes (FIG. 8) .
Our results enable insights into p53-mediated tumour suppression in humans and p53 pathway-based surveillance and treatment strategies. First, the convergence of multiple lines of evidence, both genetic and functional, strongly suggests that p53-dependent tumour suppression is highly sensitive to inherited genetic variation, whether it is rare, highly penetrant mutations (as occurs in patients with LFS) 15 or common, lower-penetrant variants (SNPs) reported in this Analysis, and that this sensitivity can contribute to the observed heterogeneity of cancer risk in the broader population. It is intriguing to speculate that the identified cancer GWAS SNPs in p53 pathway genes could aid in risk assessment for a broad range of cancers, potentially informing asymptomatic screening for earlystage cancer diagnosis, when curative interventions are possible. Indeed, such p53 pathway risk biomarkers are needed to define the heterogeneity of age-dependent and organ-dependent cancer risk seen among families with LFS, which remains a major hurdle in designing effective screening programmes to reduce the substantial morbidity and mortality associated with a genetically weakened p53 pathway 14 . Moreover, in order to maximize the prognostic value of SNPs in the broader population, the known interactions of the p53 pathway members can serve as starting points to explore possible interactions between cancer GWAS SNPs, as well as possible interactions of SNPs with the somatic mutations frequently found in the same genes. However, one caveat is that GWAS SNPs identified in large heterogeneous population studies have relatively small effect sizes, and/or may be at low population frequency, and therefore such SNPs cannot easily be tested in small studies with mixed clinical phenotypes. Thus, assessing the clinical impact of p53 pathway SNP genotypes will require careful selection of large clinical populations with well-characterized tumour mutations, treatment protocols and follow-up. Stratification of patients based on somatic mutation signature or on SNP genotype are both possible strategies. Another insight into p53 biology and its role in tumour suppression comes from our analysis of susceptibility loci for major disease groupings other than cancer, for which sufficient GWAS data were available to interrogate (FIGS 5, 6 ). The p53 stress response pathway has been implicated in the pathogenesis of many diseases, including neurological [52] [53] [54] [55] [56] , cardiovascular 57, 58 and infectious 59, 60 diseases. Indeed in our analysis, we have found SNPs in p53 pathway genes that overlap susceptibility loci for other, non-cancerous diseases (Supplementary information S16 (table) ). However, we did not find p53 pathway genes to be significantly enriched in susceptibility loci for any other major disease groupings. These included diseases of the nervous, circulatory, digestive and musculoskeletal systems. Similar observations have been made in LFS families carrying highly penetrant TP53 mutations and in mice carrying Trp53 mutations, whereby carriers have a dramatically high risk of developing a broad range of cancers, but not other diseases 14, 85 .
A clearer picture will emerge with the accrual of more data on the genetic basis of human disease susceptibility. Indeed, a challenge of the GWAS design is the necessity for large patient cohorts to compensate for the much needed multiple hypothesis testing correction. Thus, a limitation to this Analysis is that for rarer diseases and syndromes in which p53 (mis-)activity is implicated, sufficiently large studies have yet to be completed and thus cannot be thoroughly examined [86] [87] [88] [89] . However, the data generated in GWAS thus far indicate that genetic differences in the p53 pathway primarily affect susceptibility to cancer, rather than other major diseases such as Alzheimer disease, multiple sclerosis, coronary heart disease, type 2 diabetes or schizophrenia.
The most unexpected insight into p53-dependent tumour suppression arose from one of the most striking findings of our Analysis, namely the strong similarities between the causal, somatic mutations and the inherited, cancer-associated SNPs of the p53 pathway. Specifically, we found that both classes of genetic variant occur in a high proportion of p53 pathway genes in multiple cancer types, and in similar genes. Together, these observations suggest that certain genes in p53 signalling are highly sensitive to both heritable and somatic genetic variants, resulting in differential tumour suppression in multiple tissue types. The importance of all these genes in cancer has been demonstrated in mouse models [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] . This group of genes encodes important known regulators and effectors of p53-dependent stress signalling 70, [107] [108] [109] [110] [111] [112] [113] . Indeed, it has been conclusively demonstrated that moderate alterations in expression levels of these genes through genome engineering of mice can lead to differences in cancer risk and progression 93, [114] [115] [116] [117] [118] [119] . We observe the occurrence of cancer-associated SNPs in somatically mutated p53 pathway genes that are upstream regulators of p53 signalling (TP53, ATM, MDM4 and CDKN2A) and key effector genes for both cell cycle arrest (CCND1, CCND2 and CCNE1) and apoptosis (FAS and CASP8). This human genetic evidence for their central roles in regulating or affecting p53-dependent tumour suppression suggests that targeting these genes and their protein products could prove an efficient method of modulating p53 signalling in a clinical setting, compared with other pathway genes and proteins.
As agents that modulate the levels of p53 signalling are entering the clinic 28 , our observations also suggest that high-frequency inherited p53 pathway variants should be considered when designing and testing patient stratification strategies. Such information could prove useful for explaining and predicting potential side effects, as well as in understanding responsiveness to conventional and targeted cancer therapies 28, 30 . For example, numerous compounds that aim to restore the function of specific components of the p53 pathway, such as upstream regulators or downstream targets, are being developed or are currently in clinical trials. These therapeutics may vary in efficacy and also in the on-target or off-target side effects that they display 28 and we hypothesize that p53 pathway SNPs may modulate some of this variation. The added information about the inherent differences in p53 signalling gained by these easily accessible and measurable biomarkers could contribute to improving the efficacy of p53 pathway-based surveillance and treatment strategies, which has been lacking in the vast majority of cases 28 .
